Association of Neoadjuvant Pembrolizumab for OCSCC With Adverse Events After Surgery

alexandrossfakianakis shared this article with you from Inoreader Association of Neoadjuvant Pembrolizumab for OCSCC With Adverse Events After Surgery via JAMA Otolaryngology–Head & Neck Surgery Current Issue This cohort study evaluates the incidence of postoperativ e adverse events in treatment-naive patients receiving neoadjuvant pembrolizumab for advanced oral cavity cancer when compared with matched controls. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.